SEER Inquiry System - Search

First Course Therapy/Neoadjuvant Treatment:  How are Neoadjuvant Therapy--Clinical Response and Neoadjuvant Therapy--Treatment Effect coded when the neoadjuvant therapy was not completed? Does the entire course of neoadjuvant therapy need to be completed before we can code these fields? See Discussion.

Reportability/Brain and CNS:  Is a 2021 case of ecchordosis physaliphora (lesion within the prepontine cistern) on brain MRI reportable?

Reportability:  What American College of Radiology Reporting and Data Systems (RADS) can be used to determine reportability?  See Discussion.

Update to Current Manual/Neoadjuvant Therapy--Pancreas:  How are the neoadjuvant items coded for a patient who has unresectable pancreatic cancer and starts chemotherapy but will be evaluated after X cycles to see if patient may become a surgical candidate?

Solid Tumor Rules (2018/2021)/Multiple Primaries--Corpus Uteri:  How many primaries should be reported when a hysterectomy identifies primary endometrial carcinosarcoma (8980/3) and the endometrium has a background of endometrioid intraepithelial neoplasia (EIN) (8380/2)? A tumor size is provided for the carcinosarcoma, but not the background EIN.

Hormone Therapy--Breast:  How are hormone therapy (HT) and other related data items coded when a patient had a previous breast primary and is still on HT when diagnosed with a new breast primary? See Discussion.

Solid Tumor Rules (2018/2021)/Histology--Breast:  How is histology coded for a diagnosis of invasive mammary neuroendocrine tumor (NET), grade 2/3? See Discussion.

Histology/Reportability--Digestive System: Is “neuroendocrine neoplasm” reportable?  See Discussion.

EOD 2018/Summary Stage 2018--Intrahepatic Bile Duct:  How should Extent of Disease (EOD) Primary Tumor (PT) be coded for invasion of or into (but not through) the visceral peritoneum for an intrahepatic bile duct primary?  See Discussion.

Mets at Diagnosis Fields/Primary Site--Lymph Nodes:  How are the Mets at Diagnosis fields coded when the metastatic adenocarcinoma involves only one lymph node area and the primary site is unknown?  See Discussion.